Exploring anti-TGF-β therapies in cancer and fibrosis

Growth Factors

Volumn 29, Issue 4, 2011, Pages 140-152

  Hawinkels, Lukas J A C ^a   Ten Dijke, Peter ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

ALK5; Cancer; Clinical trial; Fibrosis; Smad; TGF

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ANTIFIBROTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 11014; AVOTERMIN; BELAGENPUMATUCEL; BEVACIZUMAB; CANCER VACCINE; DISITERTIDE; FRESOLIMUMAB; GW 788388; HYBRID PROTEIN; LERDELIMUMAB; LOSARTAN; LUCANIX; LY 2109761; LY 238770; METELIMUMAB; P 17; PROTEIN KINASE INHIBITOR; RECOMBINANT RECEPTOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; SD 208; SM 16; SOLUBLE BETAGLYCAN; SOLUBLE BETAGLYCAN FC FUSION PROTEIN; TASISULAM; TRABEDERSEN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; ARTICLE; BIOLOGICAL THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROGENESIS; FIBROSIS; FOCAL GLOMERULOSCLEROSIS; GLIOBLASTOMA; GLIOMA; HEART INFARCTION; HEART PROTECTION; HUMAN; IMMUNOPATHOGENESIS; INTRACELLULAR SIGNALING; LIVER FIBROSIS; LUNG CANCER; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MARFAN SYNDROME; MELANOMA; METASTASIS INHIBITION; NEOPLASM; NONHUMAN; PANCREAS CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; SCAR FORMATION; SKIN FIBROSIS; SOLID TUMOR; STOMACH CANCER; STOMACH CARCINOGENESIS; SYSTEMIC SCLEROSIS;

ANTIBODIES, NEUTRALIZING; FIBROSIS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 79960364782     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2011.595411     Document Type: Article

References (143)

1. Akhurst RJ, Derynck R. 2001. TGF-b signaling in cancer\a double-edged sword. Trends Cell Biol 11:S44-S51.
2. Angenete E, Langenskiold M, Palmgren I, Falk P, Oresland T, Ivarsson ML. 2007. Transforming growth factor b1 in rectal tumour, mucosa and plasma in relation to radiotherapy and clinical outcome in rectal cancer patients. Int J Colorectal Dis 22:1331-1338. (Pubitemid 47456718)
3. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, Prieto-Sanchez RM, Barba I, Martinez-Saez E, Prudkin L, Cuartas I, Raventos C, Martinez-Ricarte F, Poca MA, Garcia-Dorado D, Lahn MM, Yingling JM, Rodon J, Sahuquillo J, Baselga J, Seoane J. 2010. TGF-b receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18:655-668.
4. Annes JP, Munger JS, Rifkin DB. 2003. Making sense of latent TGF-b activation. J Cell Sci 116:217-224. (Pubitemid 36163863)
5. Arribillaga L, Dotor J, Basagoiti M, Riezu-Boj JI, Borras-Cuesta F, Lasarte JJ, Sarobe P, Cornet ME, Feijoo E. 2011. Therapeutic effect of a peptide inhibitor of TGF-b on pulmonary fibrosis. Cytokine 53:327-333.
6. Asano Y. 2010. Future treatments in systemic sclerosis. J Dermatol 37:54-70.
7. August P, Suthanthiran M. 2006. Transforming growth factor-b signaling, vascular remodeling, and hypertension. N Engl J Med 354:2721-2723.
8. BandyopadhyayA, Zhu Y, Cibull ML, Bao L, ChenC, SunL.1999. A soluble transforming growth factor-b type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res 59:5041-5046. (Pubitemid 29472913)
9. Bandyopadhyay A, Wang L, Lopez-Casillas F, Mendoza V, Yeh IT, Sun L. 2005. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metallopro-teinase-9 expression in a human xenograft model of prostate cancer. Prostate 63:81-90. (Pubitemid 40365392)
10. Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K, Sun LZ. 2010. Doxorubicin in combination with a small TGF-b inhibitor: A potential novel therapy for metastatic breast cancer in mouse models. PLoS One 5:e10365.
11. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. 1994. Transforming growth factor-b activation in irradiated murine mammary gland. J Clin Invest 93:892-899.
12. Beck C, Schreiber H, Rowley D. 2001. Role of TGF-b in immune-evasion of cancer. Microsc Res Tech 52:387-395.
13. Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C, Suman F, Rivetti C, Migliaretti G, Camandona M, Palestro G, Emanuelli G, Rodeck U. 2001. Differential expression of transforming growth factors-b1,-b2 and-b3 in human colon carcinoma. Eur J Cancer 37:224-233. (Pubitemid 32144700)
14. Benigni A, Zoja C, Campana M, Corna D, Sangalli F, Rottoli D, Gagliardini E, Conti S, Ledbetter S, Remuzzi G. 2006. Beneficial effect of TGF-b antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol 104:e158-e168. (Pubitemid 44885063)
15. Bennett WP, el-Deiry WS, Rush WL, Guinee DG, Jr, Freedman AN, Caporaso NE, Welsh JA, Jones RT, Borkowski A, Travis WD, Fleming MV, Trastek V, Pairolero PC, Tazelaar HD, Midthun D, Jett JR, Liotta LA, Harris CC. 1998. p21waf1/cip1 and transforming growth factor-b1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res 4: 1499-1506. (Pubitemid 28265234)
16. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744.
17. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I, Zaaroor M, Jachimczak P, Ludwig S, Schmaus S, Heinrichs H, Schlingensiepen KH. 2011. Targeted therapy for high-grade glioma with the TGF-b2 inhibitor trabedersen: Results of a randomized and controlled phase IIb study. Neuro Oncol 13:132-142.
18. Connolly EC, Saunier EF, Quigley D, Luu MT, de SA, Hann B, Yingling JM, Akhurst RJ. 2011. Outgrowth of carcinomas expressing drug-resistant P-Smad2 and markers of tumor aggression after long term TbRI/II kinase inhibition with LY2109761. Cancer Res 71:2339-2349.
19. Dennler S, Itoh S, Vivien D, ten DP, Huet S, Gauthier JM. 1998. Direct binding of Smad3 and Smad4 to critical TGF-b-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17:3091-3100. (Pubitemid 28254381)
20. Denton CP, Abraham DJ. 2001. Transforming growth factor-b and connective tissue growth factor: Key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 13:505-511. (Pubitemid 33070969)
21. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen F, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR. 2007. Recombinant human anti-transforming growth factor-b1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56:323-333. (Pubitemid 46106206)
22. Derynck R, Akhurst RJ, Balmain A. 2001. TGF-b signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129. (Pubitemid 32952643)
23. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y. 2006. Determination of TGF-b1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 94:239-246. (Pubitemid 43151542)
24. Dietz HC, Pyeritz RE. 1995. Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet 4 Spec No:1799-1809.
25. Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NA, Picariello L, Cazzola P, Monteleone G, Tonelli F, Corazza GR, MacDonald TT, Pender SL. 2009. Transforming growth factor-b signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 58:777-789.
26. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. 2007. The type III TGF-b receptor suppresses breast cancer progression. J Clin Invest 117:206-217. (Pubitemid 46048467)
27. Dotor J, Lopez-Vazquez AB, Lasarte JJ, Sarobe P, Garcia-Granero M, Riezu-Boj JI, Martinez A, Feijoo E, Lopez-Sagaseta J, Hermida J, Prieto J, Borras-Cuesta F. 2007. Identification of peptide inhibitors of transforming growth factor-b1 using a phage-displayed peptide library. Cytokine 39:106-115. (Pubitemid 47513834)
28. Ehata S, Johansson E, Katayama R, Koike S, Watanabe A, Hoshino Y, Katsuno Y, Komuro A, Koinuma D, Kano MR, Yashiro M, Hirakawa K, Aburatani H, Fujita N, Miyazono K. 2011. Transforming growth factor-b decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene 30(14):1693-1705.
29. Ezquerro IJ, Lasarte JJ, Dotor J, Castilla-Cortazar I, Bustos M, Penuelas I, Blanco G, Rodriguez C, Lechuga MC, Greenwel P, Rojkind M, Prieto J, Borras-Cuesta F. 2003. A synthetic peptide from transforming growth factor b type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 22:12-20. (Pubitemid 37222298)
30. Ferguson MW, Duncan J, Bond J, Bush J, Durani P, So K, Taylor L, Chantrey J, Mason T, James G, Laverty H, Occleston NL, Sattar A, Ludlow A, O'Kane S. 2009. Prophylactic administration of avotermin for improvement of skin scarring: Three double-blind, placebo-controlled, phase I/II studies. Lancet 373:1264-1274.
31. Figueroa JD, Flanders KC, Garcia-Closas M, Anderson WF, Yang XR, Matsuno RK, Duggan MA, Pfeiffer RM, Ooshima A, Cornelison R, Gierach GL, Brinton LA, Lissowska J, Peplonska B, Wakefield LM, Sherman ME. 2010. Expression of TGF-b signaling factors in invasive breast cancers: Relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat 121:727-735.
32. Folkman J. 2007. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286. (Pubitemid 46505878)
33. Fransvea E, Angelotti U, Antonaci S, Giannelli G. 2008. Blocking transforming growth factor-b up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47:1557-1566. (Pubitemid 351702739)
34. Fu K, Corbley MJ, Sun L, Friedman JE, Shan F, Papadatos JL, Costa D, Lutterodt F, Sweigard H, Bowes S, Choi M, Boriack-Sjodin PA, Arduini RM, Sun D, Newman MN, Zhang X, Mead JN, Chuaqui CE, Cheung HK, Zhang X, Cornebise M, Carter MB, Josiah S, Singh J, Lee WC, Gill A, Ling LE. 2008. SM16, an orally active TGF-b type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol 28:665-671. (Pubitemid 351651335)
35. Ganapathy V, GeR, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M. 2010. Targeting the transforming growth factor-b pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 9:122.
36. George J, Roulot D, Koteliansky VE, Bissell DM. 1999. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor b type II receptor: A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 96:12719-12724. (Pubitemid 29513569)
37. Goss PE, Chambers AF. 2010. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer10:871-877.
38. Grau AM, Wen W, Ramroopsingh DS, Gao YT, Zi J, Cai Q, Shu XO, Zheng W. 2008. Circulating transforming growth factor-b1 and breast cancer prognosis: Results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 112:335-341.
39. Grehn F, Hollo G, Khaw P, Overton B, Wilson R, Vogel R, Smith Z. 2007. Factors affecting the outcome of trabeculectomy: An analysis based on combined data from two phase III studies of an antibody to transforming growth factor b2, CAT-152. Ophthalmology 114:1831-1838.
40. Halder SK, Beauchamp RD, Datta PK. 2005. A specific inhibitor of TGF-b receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 7:509-521. (Pubitemid 40791869)
41. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144:646-674.
42. Haritunians T, Gueller S, O'Kelly J, Ilaria R, Jr, Koeffler HP. 2008. Novel acyl sulfonamide LY573636-sodium: Effect on hemato-poietic malignant cells. Oncol Rep 20:1237-1242.
43. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. 2001. Transforming growth factor-b1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91: 964-971.
44. Hassane S, Leonhard WN, van der Wal A, Hawinkels LJ, Lantinga-van Leeuwen IS, ten Dijke P, Breuning MH, de Heer E, Peters DJ. 2010. Elevated TGF-b-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease. J Pathol 222:21-31.
45. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, Pichler J, Wurm G, Mehdorn M, Strege R, Schuierer G, Villarrubia V, Fellner F, Jansen O, Straube T, Nohria V, Goldbrunner M, Kunst M, Schmaus S, Stauder G, Bogdahn U, Schlingensiepen KH. 2007. Inhibition of TGF-b2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies. Oligonucleotides 17:201-212. (Pubitemid 47124417)
46. Hau P, Jachimczak P, Bogdahn U. 2009. Treatment of malignant gliomas with TGF-b2 antisense oligonucleotides. Expert Rev Anticancer Ther 9:1663-1674.
47. Hawinkels LJ, Verspaget HW, van Duijn W, van der Zon JM, Zuidwijk K, Kubben FJ, Verheijen JH, Hommes DW, Lamers CB, Sier CF. 2007. Tissue level, activation and cellular localisation of TGF-b1 and association with survival in gastric cancer patients. Br J Cancer 97:398-404. (Pubitemid 47196749)
48. Hawinkels LJ, Zuidwijk K, Verspaget HW, Jonge-Muller ES, Duijn W, Ferreira V, Fontijn RD, David G, Hommes DW, Lamers CB, Sier CF. 2008. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 44:1904-1913.
49. Hawinkels L, Verspaget HW, van der Reijden JJ, Van der Zon J, Verheijen JH, Hommes D, Lamers C, Sier C. 2009. Active TGF-b1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence. Cancer Sci 100: 663-670.
50. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, ten Dijke P. 2010. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 70:4141-4150.
51. Huber MA, Kraut N, Beug H. 2005. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548-558. (Pubitemid 41267170)
52. Hulper P, Schulz-Schaeffer W, Dullin C, Hoffmann P, Harper J, Kurtzberg L, Lonning S, Kugler W, Lakomek M, Erdlenbruch B. 2011. Tumor localization of an anti-TGF-b antibody and its effects on gliomas. Int J Oncol 38:51-59.
53. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstanti-novic Z, Subota V, Ivanisevic-Milovanovic O, Nikolic-Vuko-savljevic D. 2003. Elevated plasma levels of transforming growth factor-b1 (TGF-b1) in patients with advanced breast cancer: Association with disease progression. Eur J Cancer 39:454-461. (Pubitemid 36173689)
54. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W. 1993. The effectoftransforming growth factor-b2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immuno-suppression in malignant glioma. J Neurosurg 78:944-951. (Pubitemid 23159332)
55. Jampel HD, Roche N, Stark WJ, Roberts AB. 1990. Transforming growth factor-b in human aqueous humor. Curr Eye Res 9: 963-969. (Pubitemid 20372121)
56. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61(2):69-90.
57. Jenkins G. 2008. The role of proteases in transforming growth factor-b activation. Int J Biochem Cell Biol 40:1068-1078.
58. Juarez P, Vilchis-Landeros MM, Ponce-Coria J, Mendoza V, Hernandez-Pando R, Bobadilla NA, Lopez-Casillas F. 2007. Soluble betaglycan reduces renal damage progression in db/db mice. Am J Physiol Renal Physiol 292:F321-F329. (Pubitemid 46105272)
59. Katuri V, Tang Y, Li C, Jogunoori W, Deng CX, Rashid A, Sidawy AN, Evans S, Reddy EP, Mishra B, Mishra L. 2006. Critical interactions between TGF-b signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression. Oncogene 25: 1871-1886.
60. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. 1998. Increased expression of TGF-b receptors by scleroderma fibroblasts: Evidence for contribution of autocrine TGF-b signaling to scleroderma phenotype. J Invest Dermatol 110: 47-51. (Pubitemid 28086062)
61. Khaw P, Grehn F, Hollo G, Overton B, Wilson R, Vogel R, Smith Z. 2007. A phase III study of subconjunctival human anti-transforming growth factor-b2 monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 114:1822-1830.
62. Kjellman C, Olofsson SP, Hansson O, Von ST, Lindvall M, Nilsson I, Salford LG, Sjogren HO, Widegren B. 2000. Expression of TGF-b isoforms, TGF-b receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89:251-258. (Pubitemid 30430741)
63. Koli K, Saharinen J, Hyytiainen M, Penttinen C, Keski-Oja J. 2001. Latency, activation, and binding proteins of TGF-b. Microsc Res Tech 52:354-362. (Pubitemid 32167823)
64. Komesli S, Vivien D, Dutartre P. 1998. Chimeric extracellular domain type II transforming growth factor (TGF)-b receptor fused to the Fc region of human immunoglobulin as a TGF-b antagonist. Eur J Biochem 254:505-513. (Pubitemid 28308100)
65. Kong FM, Washington MK, Jirtle RL, Anscher MS. 1996. Plasma transforming growth factor-b1 reflects disease status in patients with lung cancer after radiotherapy: A possible tumor marker. Lung Cancer 16:47-59. (Pubitemid 27062608)
66. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. 1999. Plasma transforming growth factor-b1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86:1712-1719. (Pubitemid 29513039)
67. Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T. 1990. Co-localization of transforming growth factor b2 with a1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 86:917-922. (Pubitemid 20327384)
68. Langenskiold M, Holmdahl L, Falk P, Angenete E, Ivarsson ML. 2008. Increased TGF-b 1 protein expression in patients with advanced colorectal cancer. J Surg Oncol 97:409-415. (Pubitemid 351466383)
69. LianR, ChenY, Xu Z, Zhang X. 2010. Soluble transforming growth factor-b1 receptor II might inhibit transforming growth factor-b-induced myofibroblast differentiation and improve ischemic cardiac function after myocardial infarction in rats. Coron Artery Dis 21:369-377.
70. Liao S, Liu J, Lin PC, Shi T, Jain RK, Xu L. 2011. TGF-b blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma model. Clin Cancer Res 17:1415-1424.
71. Lin HY, Moustakas A, Knaus P, Wells RG, Henis YI, Lodish HF. 1995. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-b receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-b ligands. J Biol Chem 270:2747-2754.
72. Lonn P, Moren A, Raja E, Dahl M, Moustakas A. 2009. Regulating the stability of TGFb receptors and Smads. Cell Res 19:21-35.
73. Lutty GA, Merges C, Threlkeld AB, Crone S, McLeod DS. 1993. Heterogeneity in localization of isoforms of TGF-b in human retina, vitreous, and choroid. Invest Ophthalmol Vis Sci 34: 477-487. (Pubitemid 23095198)
74. Maeda S, Dean DD, Gay I, Schwartz Z, Boyan BD. 2001. Activation of latent transforming growth factor b1 by stromelysin 1 in extracts of growth plate chondrocyte-derived matrix vesicles. J Bone Miner Res 16:1281-1290. (Pubitemid 32574657)
75. Maeda S, Dean DD, Gomez R, Schwartz Z, Boyan BD. 2002. The first stage of transforming growth factor b1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). Calcif Tissue Int 70:54-65. (Pubitemid 36934737)
76. Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, Baba H, Kohnoe S, Sugimachi K. 1999. Role of transforming growth factor-b1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 17:607-614. (Pubitemid 29075249)
77. Massague J. 2008. TGF-b in cancer. Cell 134:215-230.
78. Massague J, Seoane J, Wotton D. 2005. Smad transcription factors. Genes Dev 19:2783-2810. (Pubitemid 41739965)
79. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN. 1992. Effect of the expression of transforming growth factor-b2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 76:799-804.
80. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. 2009. Inhibition of transforming growth factor-b receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 50:1140-1151.
81. McCormick LL, Zhang Y, Tootell E, Gilliam AC. 1999. Anti-TGF-b treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: A model for human scleroderma. J Immunol 163:5693-5699.
82. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. 2003. Evaluation of anti-TGF-b2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 44:3394-3401. (Pubitemid 36909776)
83. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. 2008. LY2109761, a novel transforming growth factor-b receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7:829-840. (Pubitemid 351551036)
84. Meulmeester E, ten Dijke P. 2011. The dynamic roles of TGF-b in cancer. J Pathol 223:205-218.
85. Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V,Dunn LK, Mauviel A, Guise TA. 2011. TGF-b-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 71: 175-184.
86. Mori Y, Ishida W, Bhattacharyya S, Li Y, Platanias LC, Varga J. 2004. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor-b responses in skin fibroblasts. Arthritis Rheum 50:4008-4021. (Pubitemid 39643950)
87. Naef M, Ishiwata T, Friess H, Buchler MW, Gold LI, Korc M. 1997. Differential localization of transforming growth factor-b isoforms in human gastric mucosa and overexpression in gastric carcinoma. Int J Cancer 71:131-137. (Pubitemid 27252979)
88. Nagaraj NS, Datta PK. 2010. Targeting the transforming growth factor-b signaling pathway in human cancer. Expert Opin Investig Drugs 19:77-91.
89. Nakamura M, Katano M, Kuwahara A, Fujimoto K, Miyazaki K, Morisaki T, Mori M. 1998. Transforming growth factor b1 (TGF-b1) is a preoperative prognostic indicator in advanced gastric carcinoma. Br J Cancer 78:1373-1378. (Pubitemid 28495253)
90. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM. 2008. Transforming growth factor b subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68:3915-3923.
91. Naumann U, Maass P, Gleske AK, Aulwurm S, Weller M, Eisele G. 2008. Glioma gene therapy with soluble transforming growth factor-b receptors II and III. Int J Oncol 33:759-765.
92. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. 2006. Phase II study of belagenpuma-tucel-L, a transforming growth factor b-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24:4721-4730. (Pubitemid 46630936)
93. Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H. 2009. Phase II trial of Belagenpumatucel-L, a TGF-b2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 16:620-624.
94. Nikolic-Vukosavljevic D, Todorovic-Rakovic N, Demajo M, Ivanovic V, Neskovic B, Markicevic M, Neskovic-Konstantino-vic Z. 2004. Plasma TGF-b1-related survival of postmenopausal metastatic breast cancer patients. Clin Exp Metastasis 21: 581-585.
95. Oft M, Heider KH, Beug H. 1998. TGF-b signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8: 1243-1252. (Pubitemid 28540052)
96. Oshitani N, Yamagami H, Watanabe K, Higuchi K, Arakawa T. 2007. Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease. Gut 56:599-600. (Pubitemid 46580523)
97. Padua D, Massague J. 2009. Roles of TGF-b in metastasis. Cell Res 19:89-102.
98. Park YE, Choi YH, Lee WY, Choi KC. 1997. Transforming growth factor-b1 expression in gastric carcinoma. J Korean Med Sci 12:215-220.
99. Park D, Son HJ, Song SY, Choe WH, Lim YJ, Park SJ, Kim JJ, Kim YH, Rhee PL, Paik SW, Rhee JC, Choi KW. 2002. Role of TGF-b1 and TGF-b type II receptor in gastric cancer. Korean J Intern Med 17:160-166.
100. Pasquale LR, Dorman-Pease ME, Lutty GA, Quigley HA, Jampel HD. 1993. Immunolocalization of TGF-b1, TGF-b2, and TGF-b3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci 34:23-30. (Pubitemid 23045098)
101. Petersen M, Thorikay M, Deckers M, van DM, Grygielko ET, Gellibert F, de Gouville AC, Huet S, ten Dijke P, Laping NJ. 2008. Oral administration of GW788388, an inhibitor of TGF-b type I and II receptor kinases, decreases renal fibrosis. Kidney Int 73:705-715. (Pubitemid 351323246)
102. Pohlers D, Brenmoehl J, Loffler I, Muller CK, Leipner C, Schultze-Mosgau S, Stallmach A, Kinne RW, Wolf G. 2009. TGF-b and fibrosis in different organs\molecular pathway imprints. Biochim Biophys Acta 1792:746-756.
103. Prud'homme GJ. 2007. Pathobiology of transforming growth factor-b in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87:1077-1091.
104. Querfeld C, Eckes B, Huerkamp C, Krieg T, Sollberg S. 1999. Expression of TGF-b1,-b2 and-b3 in localized and systemic scleroderma. J Dermatol Sci 21:13-22. (Pubitemid 29347106)
105. Radonic T, de WP, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M. 2010. Losartan therapy in adults with Marfan syndrome: Study protocol of the multi-center randomized controlled COMPARE trial. Trials 11:3.
106. Roberts AB, Wakefield LM. 2003. The two faces of transforming growth factor-b in carcinogenesis. Proc Natl Acad Sci USA 100: 8621-8623. (Pubitemid 36899145)
107. Roth GJ, Heckel A, Brandl T, Grauert M, Hoerer S, Kley JT, Schnapp G, Baum P, Mennerich D, Schnapp A, Park JE. 2010. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor-b receptor I (TGFbRI). J Med Chem 53:7287-7295.
108. Rowland-Goldsmith MA, Maruyama H, Matsuda K, Idezawa T, Ralli M, Ralli S, Korc M. 2002. Soluble type II transforming growth factor-b receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 1:161-167.
109. Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD. 2004. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 50:1319-1331. (Pubitemid 38480843)
110. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N. 1999. The expression of transforming growth factor-b1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 86:1455-1462. (Pubitemid 29489778)
111. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N. 2000. An elevated serum level of transforming growth factor-b1 (TGF-b1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 20:4489-4493. (Pubitemid 32141808)
112. Samuels V, Barrett JM, Bockman S, Pantazis CG, Allen MB, Jr. 1989. Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. Am J Pathol 134: 894-902.
113. Santiago B, Gutierrez-Canas I, Dotor J, Palao G, Lasarte JJ, Ruiz J, Prieto J, Borras-Cuesta F, Pablos JL. 2005. Topical application of a peptide inhibitor of transforming growth factor-b1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 125:450-455.
114. Saunier EF, Akhurst RJ. 2006. TGF-b inhibition for cancer therapy. Curr Cancer Drug Targets 6:565-578.
115. Schlingensiepen KH, Bischof A, Egger T, Hafner M, Herrmuth H, Jachimczak P, Kielmanowicz M, Niewel M, Zavadova E, Stauder G. 2004. The TGF-b1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies. J Clin Oncol 22:3132.
116. Schlingensiepen R, Goldbrunner M, Szyrach MN, Stauder G, Jachimczak P, Bogdahn U, Schulmeyer F, Hau P, Schlingensie-pen KH. 2005. Intracerebral and intrathecal infusion of the TGF-b2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: Toxicology and safety. Oligonucleotides 15:94-104. (Pubitemid 40967415)
117. Schultze-Mosgau S, Kopp J, Thorwarth M, Rodel F, Melnychenko I, Grabenbauer GG, Amann K, Wehrhan F. 2006. Plasminogen activator inhibitor-I-related regulation of procollagen I a1 and a2 by anti-transforming growth factor-b1 treatment during radiation-impaired wound healing. Int J Radiat Oncol Biol Phys 64:280-288. (Pubitemid 41831238)
118. Shi Y, Massague J. 2003. Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell 113:685-700. (Pubitemid 36724933)
119. Siriwardena D, Khaw PT, King AJ, Donaldson ML, Overton BM, Migdal C, Cordeiro MF. 2002. Human anti-transforming growth factor b2 monoclonal antibody\a new modulator of wound healing in trabeculectomy: A randomized placebo controlled clinical study. Ophthalmology 109:427-431. (Pubitemid 34184907)
120. Snowden N, Coupes B, Herrick A, Illingworth K, Jayson MI, Brenchley PE. 1994. Plasma TGF-b in systemic sclerosis: A cross-sectional study. Ann Rheum Dis 53:763-767.
121. Subramaniam V, Chakrabarti R, Prud'homme GJ, Jothy S. 2010. Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anticancer Drugs 21: 351-361.
122. Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR, Albelda SM. 2004. Soluble type II transforming growth factor-b receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 10:5907-5918. (Pubitemid 39180973)
123. ten Dijke P, Hill CS. 2004. New insights into TGF-b-Smad signalling. Trends Biochem Sci 29: 265-273.
124. ten Dijke P, Arthur HM. 2007. Extracellular control of TGF-b signalling in vascular development and disease. Nat Rev Mol Cell Biol 8: 857-869. (Pubitemid 47622560)
125. ten Dijke P, Goumans MJ, Pardali E. 2008. Endoglin in angiogenesis and vascular diseases. Angiogenesis 11:79-89.
126. Thompson JE, Vaughan TJ, Williams AJ, Wilton J, Johnson KS, Bacon L, Green JA, Field R, Ruddock S, Martins M, Pope AR, Tempest PR, Jackson RH. 1999. A fully human antibody neutralising biologically active human TGFb2 for use in therapy. J Immunol Methods 227:17-29. (Pubitemid 29408701)
127. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F. 2011. A phase 1, single-dose study of fresolimumab, an anti-TGF-b antibody, in treatment-resistant primary focal segmental glomerulo-sclerosis. Kidney Int 79(11):1236-1243.
128. Tripathi RC, Chan WF, Li J, Tripathi BJ. 1994. Trabecular cells express the TGF-b2 gene and secrete the cytokine. Exp Eye Res 58:523-528. (Pubitemid 24249761)
129. Tsamandas AC, Kardamakis D, Ravazoula P, Zolota V, Salakou S, Tepetes K, Kalogeropoulou C, Tsota I, Kourelis T, Makatsoris T, Karavias D, Scopa CD, Bonikos DS, Kalofonos HP, Petsas T. 2004. The potential role of TGFb1, TGFb2 and TGFb3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival. Strahlenther Onkol 180:201-208. (Pubitemid 38461544)
130. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Imai Y, Shimomukai H, Nomura Y, Matsuda Y, Matsuzawa Y. 1996. High levels of transforming growth factor-b1 in patients with colorectal cancer: Association with disease progression. Gastroenterology 110:375-382. (Pubitemid 26043869)
131. Ueno H, Sakamoto T, Nakamura T, Qi Z, Astuchi N, Takeshita A, Shimizu K, Ohashi H. 2000. A soluble transforming growth factor-b receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum Gene Ther 11:33-42. (Pubitemid 30044038)
132. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. 2004. SD-208, a novel transforming growth factor-b receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64:7954-7961. (Pubitemid 39446929)
133. Varga J, Pasche B. 2008. Antitransforming growth factor-b therapy in fibrosis: Recent progress and implications for systemic sclerosis. Curr Opin Rheumatol 20:720-728.
134. Wallace A, Kapoor V, Sun J, MrassP, WeningerW, Heitjan DF, June C, Kaiser LR, Ling LE, Albelda SM. 2008. Transforming growth factor-b receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res 14:3966-3974.
135. Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H, ten Dijke P. 2010. The TGF-b/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat, in press.
136. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. 2007. Myofibroblast contraction activates latent TGF-b1 from the extracellular matrix. J Cell Biol 179:1311-1323. (Pubitemid 350277747)
137. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, Funa K. 1995. Enhanced expression of transforming growth factor-b and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62:386-392.
138. Yamada M, Kuwano K, Maeyama T, Yoshimi M, Hamada N, Fukumoto J, Egashira K, Hiasa K, Takayama K, Nakanishi Y. 2007. Gene transfer of soluble transforming growth factor type II receptor by in vivo electroporation attenuates lung injury and fibrosis. J Clin Pathol 60:916-920. (Pubitemid 47234440)
139. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR, Merlino G, Wakefield LM. 2002. Lifetime exposure to a soluble TGF-b antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109:1607-1615. (Pubitemid 34663523)
140. Yata Y, Gotwals P, Koteliansky V, Rockey DC. 2002. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-b soluble receptor: Implications for antifibrotic therapy. Hepatol-ogy 35:1022-1030. (Pubitemid 34453999)
141. Zhang YE. 2009. Non-Smad pathways in TGF-b signaling. Cell Res 19:128-139.
142. Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, Burtrum D, Wang S, Surguladze D, Ng S, Griffith H, Balderes P, Doody J, Schwartz JD, Youssoufian H, Rowinsky EK, Ludwig DL, Witte L, Zhu Z, Wu Y. 2010. Anti-transforming growth factor-b receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res 16:1191-1205.
143. Zolota V, Batistatou A, Tsamandas AC, Iliopoulos G, Scopa CD, Bonikos DS. 2002. Immunohistochemical expression of TGF-b1, p21WAF1, p53, Ki67, and angiogenesis in gastric carcinomas: A clinicopathologic study. Int J Gastrointest Cancer 32:83-89. (Pubitemid 36748996)